Interrelationship between rheumatoid arthritis and diabetes mellitus: current insights and perspectives
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261002Keywords:
Rheumatoid arthritis, Diabetes mellitus, Insulin resistance, Cytokines, InterrelationshipAbstract
Rheumatoid arthritis (RA) and diabetes mellitus (DM) are chronic, systemic conditions with significant global health burdens. Emerging evidence suggests a bidirectional relationship between these diseases, with shared pathophysiological mechanisms, including chronic inflammation, immune dysregulation, and metabolic disturbances. This review explores the current insights into the interrelationship between RA and DM, emphasizing the role of pro-inflammatory cytokines, insulin resistance, and genetic predispositions. Additionally, it examines the impact of therapeutic interventions for RA on glycemic control and vice versa, highlighting challenges and opportunities in clinical management. Understanding these interactions is crucial for developing integrated treatment strategies, improving patient outcomes, and addressing the broader implications of coexisting RA and DM. This review article aims to provide a comprehensive perspective on the evolving knowledge in this field and to identify areas for future research.
Metrics
References
Sattar N, McInnes IB. Atherosclerosis in rheumatoid arthritis: double the risk or simply double the trouble? Arthritis Rheum. 2005;52(7):1957-9.
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303-7. DOI: https://doi.org/10.1161/01.CIR.0000054612.26458.B2
Huizinga TW, Pincus T. Inflammatory pathways in diabetes and rheumatoid arthritis. J Clin Invest. 2010;120(10):3560-8.
van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68(9):1395-400. DOI: https://doi.org/10.1136/ard.2008.094151
Giles JT, Danielides S, Szklo M, Post W, Blumenthal RS, Petri M, et al. Insulin resistance in rheumatoid arthritis: association with high-density lipoprotein dysfunction and abnormal HDL particle concentrations. Arthritis Rheum. 2015;67(5):1031-9. DOI: https://doi.org/10.1002/art.38986
Zonana-Nacach A, Santana-Sahagún E, Jiménez-Balderas FJ, Camargo-Coronel A, Sánchez-Guerrero J. Prevalence of diabetes mellitus in rheumatoid arthritis. J Rheumatol. 1996;23(6):1058-63.
Raterman HG, van Eijk IC, Voskuyl AE, Simsek S, Nurmohamed MT. The metabolic syndrome in rheumatoid arthritis: is it more than a comorbidity? Curr Rheumatol Rep. 2009;11(5):389-96.
Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105-12. DOI: https://doi.org/10.1002/art.23600
Solomon DH, Love TJ, Canning C, Schneeweiss S. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. Ann Rheum Dis. 2010;69(12):2114-7. DOI: https://doi.org/10.1136/ard.2009.125476
Dessein PH, Joffe BI. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2765-75. DOI: https://doi.org/10.1002/art.22053
Ursini F, Russo E, Ruscitti P, Giacomelli R, De Sarro G. The burden of comorbidities in rheumatoid arthritis. Int J Clin Rheumatol. 2013;8(2):149-59.
Suárez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD000957.
Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685-95. DOI: https://doi.org/10.1007/s00296-015-3415-x
Kyburz D, Corr M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol. 2003;25(1):79-90. DOI: https://doi.org/10.1007/s00281-003-0131-5
Doran MF, Pond GR, Crowson CS, O'Fallon WM, Gabriel SE. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46(3):625-31. DOI: https://doi.org/10.1002/art.509
Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1-26. DOI: https://doi.org/10.1002/art.39480
Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861-74. DOI: https://doi.org/10.1016/S0140-6736(07)60784-3
Pahwa R, Jialal I. Chronic inflammation and insulin resistance. StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Metabolic syndrome in rheumatoid arthritis. Maedica (Bucur). 2012;7(2):148-52.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7. DOI: https://doi.org/10.1038/nature05485
Crowson CS, Liao KP, Davis JM, Solomon DH, Matteson EL, Knutson KL, et al. Rheumatoid arthritis and diabetes mellitus: evidence for an association? Arthritis Care Res (Hoboken). 2013;65(2):208-15.
Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani A, Sokka T, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52(10):3045-53. DOI: https://doi.org/10.1002/art.21288
Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(9):1286-98. DOI: https://doi.org/10.1093/rheumatology/ken159
Dessein PH, Tobias M, Veller MG. Metabolic syndrome and subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol. 2006;33(12):2425-32.
Pincus T, Sokka T, Chung CP. Clinical trials in rheumatoid arthritis: design and limitations. Rheum Dis Clin North Am. 2009;35(4):851-70. DOI: https://doi.org/10.1016/j.rdc.2009.10.004
Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional and nontraditional risk factors. Arthritis Rheum. 2010;62(4):725-32.
Emamalizadeh B, Gharesouran J, Mirzaei H, Azami S, Estiar MA, Azizi S, et al. Contribution of cytokine genes to rheumatoid arthritis and diabetes susceptibility. Gene. 2017;627:244-9.
Giles JT, Danoff TM, Szklo M, Blumenthal RS, Post WS, Petri M, et al. Insulin resistance and inflammation in rheumatoid arthritis: a cross-sectional study. Arthritis Care Res (Hoboken). 2013;65(9):1499-506.
van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):184-8. DOI: https://doi.org/10.1136/ard.2006.051672
Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173-7. DOI: https://doi.org/10.1016/S0140-6736(02)08213-2
Li Z, Li X, Chen X, Ma W, Dai Z. Associations between rheumatoid arthritis and risk of diabetes mellitus: a meta-analysis and systematic review. J Diabetes Res. 2020;2020:6043297.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19. DOI: https://doi.org/10.1056/NEJMra1004965
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821-30. DOI: https://doi.org/10.1172/JCI200319451
Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007;66(2):208-14. DOI: https://doi.org/10.1136/ard.2006.054973
Saevarsdottir S, Wedrén S, Seddighzadeh M, Bengtsson C, Wesley A, Lindblad S, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and TNF inhibitors: observations from the EIRA cohort and the Swedish Rheumatology Register. Arthritis Rheum. 2011;63(1):26-36. DOI: https://doi.org/10.1002/art.27758
de Hair MJ, Landewé RB, van de Sande MG, van Schaardenburg D, van Baarsen LG, Gerlag DM, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis. 2013;72(10):1654-8. DOI: https://doi.org/10.1136/annrheumdis-2012-202254
Solomon DH, Reed GW, Kremer JM, Curtis JR, Hochberg MC, Greenberg JD, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449-55. DOI: https://doi.org/10.1002/art.39098
Kitas GD, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis. 2011;70(1):8-14. DOI: https://doi.org/10.1136/ard.2010.142133
Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233-55. DOI: https://doi.org/10.1111/j.0105-2896.2009.00859.x
Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903-11. DOI: https://doi.org/10.1016/S0140-6736(01)06075-5
Kuo CF, Chou IJ, Tseng WY, Yu KH, See LC, Chang HC, et al. Familial risk of autoimmune diseases in patients with type 1 diabetes mellitus: a population-based cohort study. Diabetologia. 2016;59(2):292-9. DOI: https://doi.org/10.1007/s00125-016-3929-0
van Steenbergen HW, Huizinga TW, van der Helm-van Mil AH. The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed? Arthritis Rheum. 2013;65(9):2219-32. DOI: https://doi.org/10.1002/art.38013
Del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional risk factors. Arthritis Rheum. 2001;44(12):2737-45. DOI: https://doi.org/10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#
Toms TE, Panoulas VF, Douglas KM, Griffiths HR, Sattar N, Smith JP, et al. Methotrexate therapy associates with a reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60 - more than just an anti-inflammatory effect? A cross-sectional study. Arthritis Res Ther. 2009;11(4):R110. DOI: https://doi.org/10.1186/ar2765
Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Review: Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol. 2014;66(4):775-82. DOI: https://doi.org/10.1002/art.38323
Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006;65(12):1608-12. DOI: https://doi.org/10.1136/ard.2005.050377
Downloads
Published
How to Cite
Issue
Section
